Adjusted HRs for all-cause, cardiovascular (CV) and non-CV mortality in each of the stratified analyses
| Strata (category A, category B) | Category A HR (95% CI) | Category B HR (95% CI) | P value for interaction test |
| CV mortality | |||
| Duration of treated diabetes (<4, ≥4) | 0.59 (0.51 to 0.69) | 0.54 (0.48 to 0.60) | 0.687 |
| Use of other thiazolidinediones (never, ever) | 0.56 (0.51 to 0.62) | 0.72 (0.55 to 0.94) | 0.111 |
| History of diabetic complications (no, yes) | 0.52 (0.45 to 0.59) | 0.63 (0.54 to 0.72) | 0.002 |
| History of macrovascular disease (no, yes) | 0.50 (0.42 to 0.58) | 0.63 (0.56 to 0.71) | <0.001 |
| History of chronic kidney disease or renal impairment (no, yes) | 0.52 (0.47 to 0.58) | 0.72 (0.60 to 0.87) | 0.008 |
| Non-CV mortality | |||
| Duration of treated diabetes (<4, ≥4) | 0.64 (0.57 to 0.72) | 0.63 (0.56 to 0.70) | 0.339 |
| Use of other thiazolidinediones (never, ever) | 0.60 (0.55 to 0.65) | 0.86 (0.69 to 1.08) | 0.004 |
| History of diabetic complications (no, yes) | 0.57 (0.51 to 0.63) | 0.69 (0.61 to 0.78) | 0.004 |
| History of macrovascular disease (no, yes) | 0.58 (0.52 to 0.64) | 0.70 (0.62 to 0.80) | <0.001 |
| History of chronic kidney disease or renal impairment (no, yes) | 0.58 (0.52 to 0.63) | 0.75 (0.64 to 0.89) | 0.013 |
| All-cause mortality | |||
| Duration of treated diabetes (<4, ≥4) | 0.62 (0.56 to 0.68) | 0.58 (0.53 to 0.63) | 0.836 |
| Use of other thiazolidinediones (never, ever) | 0.58 (0.54 to 0.62) | 0.80 (0.67 to 0.95) | 0.001 |
| History of diabetic complications (no, yes) | 0.54 (0.5 to 0.59) | 0.66 (0.60 to 0.72) | <0.001 |
| History of macrovascular disease (no, yes) | 0.55 (0.5 to 0.6) | 0.66 (0.61 to 0.72) | <0.001 |
| History of chronic kidney disease or renal impairment (no, yes) | 0.55 (0.51 to 0.59) | 0.74 (0.65 to 0.84) | <0.001 |